Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.
2.

Kinetic studies of protein farnesyltransferase mutants establish active substrate conformation.

Pickett JS, Bowers KE, Hartman HL, Fu HW, Embry AC, Casey PJ, Fierke CA.

Biochemistry. 2003 Aug 19;42(32):9741-8.

PMID:
12911316
3.

Finding a needle in the haystack: computational modeling of Mg2+ binding in the active site of protein farnesyltransferase.

Yang Y, Chakravorty DK, Merz KM Jr.

Biochemistry. 2010 Nov 9;49(44):9658-66. doi: 10.1021/bi1008358.

4.

Molecular dynamics simulations on the critical states of the farnesyltransferase enzyme.

Sousa SF, Fernandes PA, Ramos MJ.

Bioorg Med Chem. 2009 May 1;17(9):3369-78. doi: 10.1016/j.bmc.2009.03.055. Epub 2009 Apr 2.

PMID:
19369081
5.

Protein farnesyl transferase target selectivity is dependent upon peptide stimulated product release.

Troutman JM, Andres DA, Spielmann HP.

Biochemistry. 2007 Oct 9;46(40):11299-309. Epub 2007 Sep 18.

PMID:
17877368
6.

Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release.

Furfine ES, Leban JJ, Landavazo A, Moomaw JF, Casey PJ.

Biochemistry. 1995 May 23;34(20):6857-62.

PMID:
7756316
7.

Mutagenesis studies of protein farnesyltransferase implicate aspartate beta 352 as a magnesium ligand.

Pickett JS, Bowers KE, Fierke CA.

J Biol Chem. 2003 Dec 19;278(51):51243-50. Epub 2003 Oct 7.

8.

Mechanistic studies of rat protein farnesyltransferase indicate an associative transition state.

Huang C, Hightower KE, Fierke CA.

Biochemistry. 2000 Mar 14;39(10):2593-602.

PMID:
10704208
9.

Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.

Hougland JL, Hicks KA, Hartman HL, Kelly RA, Watt TJ, Fierke CA.

J Mol Biol. 2010 Jan 8;395(1):176-90. doi: 10.1016/j.jmb.2009.10.038. Epub 2009 Oct 28.

10.

A rapid and convenient filter-binding assay for ras p21 processing enzyme farnesyltransferase.

Khan SG, Mukhtar H, Agarwal R.

J Biochem Biophys Methods. 1995 Jun;30(2-3):133-44.

PMID:
7494090
12.

Computational studies of the farnesyltransferase ternary complex part I: substrate binding.

Cui G, Wang B, Merz KM Jr.

Biochemistry. 2005 Dec 20;44(50):16513-23.

13.

Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.

Sousa SF, Fernandes PA, Ramos MJ.

Curr Med Chem. 2008;15(15):1478-92. Review.

PMID:
18537624
14.

Unraveling the Catalytic Pathway of Metalloenzyme Farnesyltransferase through QM/MM Computation.

Ho MH, De Vivo M, Peraro MD, Klein ML.

J Chem Theory Comput. 2009 Jun 9;5(6):1657-66. doi: 10.1021/ct8004722.

PMID:
26609858
15.
16.

Kinetic analysis of zinc ligand mutants of mammalian protein farnesyltransferase.

Fu HW, Beese LS, Casey PJ.

Biochemistry. 1998 Mar 31;37(13):4465-72.

PMID:
9521766
17.

J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.

Yonemoto M, Satoh T, Arakawa H, Suzuki-Takahashi I, Monden Y, Kodera T, Tanaka K, Aoyama T, Iwasawa Y, Kamei T, Nishimura S, Tomimoto K.

Mol Pharmacol. 1998 Jul;54(1):1-7.

18.

Enzyme flexibility and the catalytic mechanism of farnesyltransferase: targeting the relation.

Sousa SF, Fernandes PA, Ramos MJ.

J Phys Chem B. 2008 Jul 24;112(29):8681-91. doi: 10.1021/jp711214j. Epub 2008 Jun 24.

PMID:
18572907
19.

Farnesyl diphosphate analogues with aryl moieties are efficient alternate substrates for protein farnesyltransferase.

Subramanian T, Pais JE, Liu S, Troutman JM, Suzuki Y, Leela Subramanian K, Fierke CA, Andres DA, Spielmann HP.

Biochemistry. 2012 Oct 16;51(41):8307-19. doi: 10.1021/bi3011362. Epub 2012 Oct 2.

20.

The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.

Long SB, Hancock PJ, Kral AM, Hellinga HW, Beese LS.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12948-53. Epub 2001 Oct 30.

Supplemental Content

Support Center